Arena Pharmaceuticals shares rise on weight loss drug patent

April 7, 2015

Shares of Arena Pharmaceuticals rose Tuesday after the drug developer said it received an additional patent for its weight loss drug Belviq.

Arena and its partner Eisai said approval was granted from the US Patent and Trademark Office. The patent can prevent other companies from producing a similar drug. The patent is expected to last until 2033, Arena CEO Jack Lief said in a written statement.

Belviq is designed to stimulate serotonin receptors in the brain, making patients feel full. The drug first went on sale in 2013.

San Diego-based Arena Pharmaceuticals Inc. makes and developed Belviq, while Eisai Inc., the U.S. unit of Japanese health company Eisai Co., markets the drug.

Arena shares rose 23 cents, or 5.3 percent, to $4.59 in morning trading Tuesday. Its shares are down 28 percent over the past year.

Explore further: Weight loss drug Belviq gets overdue US launch

Related Stories

Weight loss drug Belviq gets overdue US launch

June 7, 2013
Arena Pharmaceuticals says its weight loss drug Belviq will be available to U.S. patients beginning next week, nearly a year after the drug was officially approved by federal regulators.

FDA clears Novo Nordisk's weight loss drug Saxenda

December 23, 2014
The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. It's the first injectable drug approved for weight loss.

FDA approves weight-loss drug Contrave (Update)

September 11, 2014
U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.

US clears first new weight-loss pill in 13 years

June 27, 2012
(AP) — The Food and Drug Administration has approved Arena Pharmaceutical's anti-obesity pill Belviq, the first new prescription drug for long-term weight loss to enter the U.S. market in over a decade.

Pfizer painkiller gets longer patent protection (Update)

March 5, 2013
Drugmaker Pfizer Inc. said Tuesday that a new patent on one of its top drugs, anti-inflammatory painkiller Celebrex, extends its U.S. patent protection by 18 months, potentially bringing the company a few billion dollars ...

FDA panel backs Novo Nordisk injection for obesity

September 11, 2014
Federal health experts say a diabetes drug from Novo Nordisk should be approved for a new use in treating obesity.

Recommended for you

Opioid abuse leads to heroin use and a hepatitis C epidemic, researcher says

February 22, 2018
Heroin is worse than other drugs because people inject it much sooner, potentially resulting in increased risk of injection-related epidemics such as hepatitis C and HIV, a Keck School of Medicine of USC study shows.

Opioid addiction treatment behind bars reduced post-incarceration overdose deaths in RI

February 14, 2018
A treatment program for opioid addiction launched by the Rhode Island Department of Corrections was associated with a significant drop in post-incarceration drug overdose deaths and contributed to an overall drop in overdose ...

Heroin vaccine blocks lethal overdose

February 14, 2018
Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug. Their research, published ...

Study shows NIH spent >$100 billion on basic science for new medicines

February 12, 2018
Federally funded research contributed to the science underlying all new medicines approved by the FDA over the past six years, according to a new study by Bentley University.

Opioid use increases risk of serious infections

February 12, 2018
Opioid users have a significantly increased risk of infections severe enough to require treatment at the hospital, such as pneumonia and meningitis, as compared to people who don't use opioids.

Placebo pills prescribed honestly help cancer survivors manage symptoms

February 9, 2018
Long after cancer treatment ends, many continue to deal with one particular symptom that refuses to go away: fatigue. In a new study, researchers at the University of Alabama at Birmingham and Harvard Medical School have ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.